These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34461363)

  • 1. Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions.
    Ozer IS; Kuzu Kumcu M; Tezcan Aydemir S; Akbostanci MC
    Clin Neurol Neurosurg; 2021 Oct; 209():106889. PubMed ID: 34461363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.
    Scaglione F
    Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26959061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH; Cetinkaya A; Kulwin DR
    Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
    Grosset DG; Tyrrell EG; Grosset KA
    J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Botulinum toxin therapy for focal dystonia].
    Hahn K; Niklai E; Garzuly F; Szupera Z
    Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.
    Sampaio C; Ferreira JJ; Simões F; Rosas MJ; Magalhães M; Correia AP; Bastos-Lima A; Martins R; Castro-Caldas A
    Mov Disord; 1997 Nov; 12(6):1013-8. PubMed ID: 9399229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term stable efficacy of botulinum toxin A in facial movement disorders with no need for increasing dose.
    Badarny S; Ibrahim R; Susel Z; Zaina A; Nasar R; Badarny Y
    Medicine (Baltimore); 2021 Jun; 100(25):e26481. PubMed ID: 34160460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S; Susel Z; Honigman S
    Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of techniques of botulinum toxin injections for blepharospasm and hemifacial spasm.
    Sacramento DRC; Lima A; Maia DP; Cunningham M; Maciel RH; Camargos ST; Cardoso F
    Mov Disord; 2019 Sep; 34(9):1401-1403. PubMed ID: 31251420
    [No Abstract]   [Full Text] [Related]  

  • 11. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
    Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
    Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm.
    Nüssgens Z; Roggenkämper P
    Graefes Arch Clin Exp Ophthalmol; 1997 Apr; 235(4):197-9. PubMed ID: 9143885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study.
    Peyronnet B; Castel-Lacanal E; Roumiguie M; Even L; Marque P; Soulié M; Rischmann P; Game X
    Neurourol Urodyn; 2017 Mar; 36(3):734-739. PubMed ID: 27037973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
    Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
    Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm.
    Bentivoglio AR; Fasano A; Ialongo T; Soleti F; Lo Fermo S; Albanese A
    Eur J Neurol; 2009 Mar; 16(3):392-8. PubMed ID: 19364366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lacrimal film evaluation of patients with facial dystonia during botulinum toxin type A treatment].
    Costa PG; Cardoso IP; Saraiva FP; Raiza AC; Tanaka LK; Matayoshi S
    Arq Bras Oftalmol; 2006; 69(3):319-22. PubMed ID: 16936952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.
    Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G;
    Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study.
    Kongsengdao S; Kritalukkul S
    J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S48-54. PubMed ID: 22619887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with long-term treatment with albumin-supplemented botulinum toxin type A.
    Mohammadi B; Kollewe K; Wegener M; Bigalke H; Dengler R
    J Neural Transm (Vienna); 2009 Apr; 116(4):437-41. PubMed ID: 19319477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.